**General Information**

|  |
| --- |
| Name: Institution/Affiliation: Email: Phone Number:  |
| **Individuals involved in Concept, and their Role, Institution/Affiliation, and Email Addresses**Individual to Complete Assay, if applicable: Individual to Complete Biomarker Data Analysis: Individual to Complete Clinical Data Analysis: |
|  |

**Biospecimen or Data Proposal (Not to exceed 1 page)**

|  |  |
| --- | --- |
| **Assay Type or Data requested:*****(Genomics, western, proteomics, mass spec, etc.)*** |  |
| **Background:** **(not to exceed 10 lines)** |  |
| **Preliminary Results:****(not to exceed 10 lines)** |  |
| **Relevant Publications If Available or applicable (<5)** |  |
| **Primary Objective:** |  |
| **Secondary Objective:** |  |

**Assay Proposal Continued:**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
| **I-SPY COVID Specific Biomarker Patient Population:****(specific treatment arm if applicable, or all arms)** |  |
| **Sample Type Required**  | *Buffy Coat. Plasma Paxgene RNA Paxgene DNA**Citrate plasma (ideally) or serum (alternatively)* |
| **Timepoint (D0, D3, D7 are current timepoints)** | *All, plus follow-up, if available* |
| **Quantity of Sample Required For Assay** | *Ideally 50ul; 10ul as a minimum* |
| **Special Processing Required Above Current MOP? If so, please detail here including time involved, time urgency of processing, need for additional equipment, biosafety precautions, or other relevant logistical considerations.** | *NA* |

 |

**Analysis, Budget, Funding, and Timeline**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
| **General Analysis Overview*****(Not to exceed more than 1 page)*** | (A very concise, clear, and brief summary of how data from this assay would be analyzed) |
| **Assay cost per sample** | $ |
| **Supplies needed and associated cost per sample** |  |
| **Other Relevant Information/Comments:** |  |

**Submission**

|  |  |
| --- | --- |
| **Please Submit in MS WORD To:** | **Carolyn Calfee, MD MAS (PI) ISPY COVID Biomarker Working Group Chair****c/o Michael Szymanski, Project Manager****Email: m.szymanski@quantumleaphealth.org** **Please copy** **Carolyn.calfee@ucsf.edu** |

 |